Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to $330,000.

  • Heron Therapeutics' Change in Accured Expenses rose 170.87% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 463.54%. This contributed to the annual value of $330,000 for FY2024, which is 107.87% up from last year.
  • Latest data reveals that Heron Therapeutics reported Change in Accured Expenses of $330,000 as of FY2024, which was up 107.87% from -$4.2 million recorded in FY2023.
  • Over the past 5 years, Heron Therapeutics' Change in Accured Expenses peaked at $12.9 million during FY2022, and registered a low of -$6.9 million during FY2020.
  • Over the past 3 years, Heron Therapeutics' median Change in Accured Expenses value was $330,000 (recorded in 2024), while the average stood at $3.0 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 250.48% in 2020, then skyrocketed by 344.98% in 2022.
  • Heron Therapeutics' Change in Accured Expenses (Yearly) stood at -$6.9 million in 2020, then climbed by 23.24% to -$5.3 million in 2021, then skyrocketed by 344.98% to $12.9 million in 2022, then tumbled by 132.50% to -$4.2 million in 2023, then skyrocketed by 107.87% to $330,000 in 2024.